LUT017 Gel for Venous Leg Ulcers and Chronic Non-Healing Skin Wounds
This study is testing a new gel called LUT017 for adults with venous leg ulcers (VLUs) and other chronic non-healing skin wounds. VLUs are open sores on the legs caused by poor blood circulation. The study wants to see if LUT017 gel, applied once a week for up to 8 weeks, is safe and well-tolerated. Researchers will also look for early signs of whether the gel helps wounds heal. You might be able to join if you are at least 18 years old and have a VLU that has not healed for 4 weeks to 24 months, and is between 2 and 20 square centimeters in size. This study is currently recruiting 18 participants.
- Study design
- This is a Phase 1, open-label study, meaning both you and the study team will know you are receiving LUT017 gel. It plans to enroll 18 participants.
- What's involved
- You would apply LUT017 gel once weekly for up to 8 weeks directly to your venous leg ulcer or chronic non-healing cutaneous wound.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your safety and tolerability will be measured from your first dose through Week 8 (the end of the treatment period).
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
LUT017 Gel for Venous Leg Ulcers and Chronic Non-Healing Skin Wounds in Adults
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Antoni Ribas, M.D., PhD · STUDY_DIRECTOR · University of California, Los Angeles
- Steven Farley, M.D. · PRINCIPAL_INVESTIGATOR · University of California, Los Angeles
- Aksone Nouvong, MD · STUDY_CHAIR · University of California, Los Angeles
- Jessica O'Conell, MD · STUDY_CHAIR · University of California, Los Angeles
- Vincent Rowe, MD · STUDY_CHAIR · University of California, Los Angeles
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)From first dose (Day 0) through Week 8 (end of treatment period)
Number and percentage of participants experiencing treatment-emergent adverse events (AEs), including adverse drug reactions (ADRs), serious adverse events (SAEs), unexpected adverse events, AEs leading to discontinuation, and AEs leading to death. Adverse events are graded according to CTCAE criteria and assessed for relationship to study drug.